This article is more than 5 years old. Information may no longer be current.
Healionics raises $4.5 million to fund trial of vascular access graft
Click Here to Manage Email Alerts
Healionics Corporation has raised $4.5 million to help fund a trial on its new vascular access device.
The financing supports the first human study, currently underway, of the company’s STARgraft product. In preclinical studies, the company said the STARgraft demonstrated improved ability to maintain blood flow compared to on-market vascular grafts.
“We welcome the participation of a number of well-known angel and venture investors in this financing round and would also like to thank our existing investors for their continued support,” Mike Connolly, Healionics CEO, said in a press release. “The start of clinical trials is a significant milestone for the company, as we work toward our goal of regulatory approval and commercial launch of STARgraft.”
Healionics said its STARgraft vascular graft is designed to resist the problems of occlusion and infection seen among current devices. The company is also applying the biomaterial used in the STARgraft to prevent both scarring and infection in a variety of other implantable device applications, the company said.
Reference:
https://healionics.com/news/